Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,089,719 | 4,401,024 | 3,151,961 | 2,152,278 | 1,791,665 |
| Marketable Securities | 2,640,026 | 3,001,322 | 2,547,399 | 2,229,371 | 1,932,557 |
| Receivables | 10,927,900 | 9,046,744 | 10,303,120 | 8,346,416 | 8,142,708 |
| Inventories | 4,618,957 | 4,311,964 | 4,093,722 | 3,691,122 | 3,453,341 |
| Other current assets | -2 | -4 | -2 | 3 | -1 |
| TOTAL | $20,276,600 | $20,761,050 | $20,096,200 | $16,419,190 | $15,320,270 |
| Non-Current Assets | |||||
| PPE Net | 13,207,540 | 11,893,310 | 10,961,010 | 10,089,020 | 9,440,613 |
| Investments And Advances | 241,468 | 214,766 | 216,082 | 174,505 | 190,169 |
| Intangibles | 8,770,951 | 8,135,996 | 7,414,429 | 7,275,465 | 7,280,505 |
| Other Non-Current Assets | 3,166,811 | 2,809,618 | 2,330,289 | 2,070,430 | 1,930,433 |
| TOTAL | $25,386,770 | $23,053,690 | $20,921,810 | $19,609,420 | $18,841,720 |
| Total Assets | $45,663,370 | $43,814,750 | $41,018,010 | $36,028,600 | $34,161,990 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 940,606 | 965,498 | 918,823 | 180,269 | 207,586 |
| Accounts payable and accrued liabilities | 3,717,991 | 2,935,476 | 2,598,827 | 1,448,205 | 2,207,119 |
| Other current liabilities | 18,942,070 | 19,496,260 | 17,959,200 | 16,513,570 | 13,706,310 |
| TOTAL | $24,633,910 | $25,192,590 | $22,881,890 | $19,015,580 | $17,125,100 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,980,666 | 2,908,904 | 2,836,531 | 3,496,875 | 3,443,429 |
| Other Non-Current Liabilities | 1,100,616 | 985,354 | 967,182 | 871,517 | 772,003 |
| TOTAL | $5,556,804 | $5,045,468 | $4,918,018 | $5,503,179 | $5,215,270 |
| Total Liabilities | $30,190,710 | $30,238,060 | $27,799,910 | $24,518,760 | $22,340,370 |
| Shareholders' Equity | |||||
| Common Shares | 65,485 | 65,846 | 65,891 | 65,710 | 64,570 |
| Retained earnings | 15,222,620 | 13,393,310 | 12,874,040 | 11,105,790 | 11,411,120 |
| Other shareholders' equity | 185,555 | 118,534 | 278,179 | 339,340 | 346,930 |
| TOTAL | $15,472,660 | $13,576,690 | $13,218,110 | $11,509,840 | $11,821,620 |
| Total Liabilities And Equity | $45,663,370 | $43,814,750 | $41,018,020 | $36,028,600 | $34,161,990 |